Latest Breaking News On - Health promotion series - Page 1 : comparemela.com

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

United statesSouth koreaNoord hollandMichael meoMarlena abdinoorMichael korenParag mahantiJonathan grahamSloan simpsonColl cardiolHealth promotion seriesAlnylam pharmaceuticalsAmerican heart associationEuropean medicines agencyNovartis pharmaceuticals corpAmerican college of cardiology congress

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 7, 2024

United kingdomUnited statesChristine regan lindenboomJosh brodskyAkshay desaiSimon foxAlnylam pharmaceuticalsHealth promotion seriesZilebesiran program lead at alnylamWorld health organizationJournal of the american college cardiologySecurities exchangeAmerican college of cardiologyExchange commissionAlnylam pharmaceuticals nasdaqHeart failure program

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaNoord hollandDennis riedlNicole zinsli sommSatoshi sugimotoRichard jarvisIsabella zinckImke kappesSloan simpsonMichael meoMarlena abdinoorParag mahantiJonathan grahamColl cardiolMichael koren

New Novartis data show early addition of twice-yearly*

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal.

United statesSouth koreaNoord hollandJonathan grahamRichard jarvisIsabella zinckSatoshi sugimotoNicole zinsli sommColl cardiolParag mahantiMichael meoImke kappesMichael korenMarlena abdinoorSloan simpsonAmerican heart association

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaNoord hollandParag mahantiSatoshi sugimotoDavid soergelJonathan grahamMichael korenIsabella zinckMichael meoSloan simpsonColl cardiolMarlena abdinoorImke kappesRichard jarvisNicole zinsli somm